Perrigo Company plc (NYSE:PRGO) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET

Company Participants

Brad Joseph - Vice President, Investor Relations

Patrick Taylor - President and Chief Executive Officer

Eduardo Bezerra - Executive Vice President and Chief Financial Officer

Conference Call Participants

Chris Schott - JPMorgan

Alec Legg - Canaccord Genuity

Daniel Biolsi - Hedgeye

Operator

Good Day and welcome to the Perrigo Second Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode. After today’s presentation, there will be an opportunity to ask questions. [Operator instructions] Please note this event is being recorded.

I would now like to turn the conference over to Bradley Joseph, Vice President of Investor Relations and Corporate Communications. Please go ahead.

Brad Joseph

Good morning, and welcome to Perrigo’s second quarter 2023 earnings conference call. I hope you all had a chance to review our release issued this morning. A copy of the earnings release and presentation for today’s discussion are available within the Investors section of perrigo.com website. For the time, I would like to introduce and welcome Perrigo’s newly appointed President and CEO, Patrick Lockwood-Taylor to the call. Take note, as a shareholder we are thrilled to have you at Perrigo. Your consumer self-care experience and expertise will bring fresh perspective and help inspire the organization achieving the greater height. Again, welcome. Also joining this call this morning is Perrigo CFO, Eduardo Bezerra.

I’d like to remind everyone that during this call, participants will make certain forward-looking statements. Please refer to the important information for shareholders and investors and Safe Harbor language regarding these statements in our press release issued earlier this morning.

A few quick items before we start. First, unless stated, all financial results discussed and presented are on a continuing operations basis. They do not include any contributions from the divested Rx business, which was accounted for as discontinued operations prior to its sale.

Second, organic growth excludes acquisitions, divestitures, exited product lines and currency in both comparable periods. All comments related to constant currency remove the impact of currency translation versus the prior year by applying the exchange rates used in the comparable measurements in the prior year's financial statements.

And third, Patrick’s discussion will focus solely on non-GAAP results, except as otherwise expressly noted. See the appendix for additional details and for reconciliations of all non-GAAP financial measures presented.

And with that, I'd like to turn the call over to Patrick.